Neurocrine Biosciences, Inc. Stock News

SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: Jefferies Global Healthcare Conference. Fireside chat on Tuesday, November 18, 2025 at 12:00 PM GMT (7:00 AM ET) in London Piper Sandler 37th Annual Healthcare Conference.

SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo. NBI-1070770 was generally well tolerated.

The volatile sector is seeing greater stability, and these four stocks can profit.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants Todd Tushla Kyle Gano - CEO & Director Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Sanjay Keswani - Chief Medical Officer Conference Call Participants Philip Nadeau - TD Cowen, Research Division Paul Matteis - Stifel, Nicolaus & Company, In...

Neurocrine Biosciences posts standout Q3 beat as INGREZZA and CRENESSITY drive 28% product sales growth.

Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth INGREZZA® (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Year-Over-Year Growth CRENESSITY® (crinecerfont) Third-Quarter 2025 Net Product Sales of $98 Million with 540 Total New Patient Enrollment Start Forms SAN DIEGO , Oct. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences...

Neurocrine Biosciences is rated BUY, driven by strong INGREZZA sales, Prenepsi growth, and a promising late-stage neuropsychiatry pipeline. NBIX's Q2 2025 revenue reached $682 million, with INGREZZA contributing 91% and Prenepsi expanding its rare-disease market presence. Robust cash reserves of $1.8 billion and disciplined expense management position NBIX to self-fund pipeline innovation and f...

Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms 90% of participants who completed 48 weeks of continuous treatment with INGREZZA 40 mg achieved a ≥50% improvement in the Abnormal Involuntary Movement Scale Total Score INGREZZA is the only vesicular monoamine transporter 2 (VMAT2) inhibitor that allows...